Summary
Aduro BioTech, Inc. (Aduro BioTech) is a clinical-stage cancer immunotherapy company. It focuses on developing technology platforms that induce highly targeted, potent and lasting immune responses against a variety of cancers. The company harnesses its lead technology platform, live, attenuated, double-deleted (LADD) Listeria mononcytogenes. Its other technology platform consists of cyclic dinucleotides (CDN) technology, which helps stimulate the intracellular STING pathway. Its pipeline products under LADD platform include CRS-207, indicated for the treatment of pancreatic and ovarian cancers, and mesothelioma; ADD-623, indicated for the treatment of gliomas; ADU-741 (prostate cancer); and ADU-214 (lung cancer). The FDA granted Breakthrough Therapy designation for its lead combination of CRS-207 and GVAX Pancreas in pancreatic cancer. Its product candidates under CDN platform include ADU-S100, indicated for the treatment of palpable tumors. Aduro BioTech is headquartered in Berkeley, California, the US.
Aduro BioTech, Inc. (ADRO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Aduro BioTech, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Venture Financing 15
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 19
Aduro BioTech Raises US$6.5 Million In Venture Financing 20
Aduro BioTech Secures US$0.5 Million In Venture Financing 21
Aduro BioTech Secures US$19.25 Million In Series B Financing 22
Aduro BioTech Raises US$0.77 Million In Venture Financing 23
Partnerships 24
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 26
Licensing Agreements 28
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 28
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 29
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 31
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 32
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 35
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 37
Aduro BioTech Enters into Licensing Agreement with UCB 38
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 40
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 41
Equity Offering 43
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 45
Acquisition 47
Aduro Biotech to Acquire BioNovion 47
Consegna Group Completes Acquisition Of Aspen Medisys 48
Aduro BioTech, Inc. - Key Competitors 50
Key Employees 51
Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53
List of Tables
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Aduro BioTech, Inc., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Aduro BioTech, Inc., Deals By Therapy Area, 2010 to YTD 2016 9
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Aduro BioTech Acquires GVAX Assets From BioSante Pharma 13
Aduro BioTech Raises USD51.4 Million in Series D Venture Financing 15
Aduro BioTech Raises USD55 Million in Series C Financing 17
Aduro BioTech Raises US$7 Million In Venture Financing 19
Aduro BioTech Raises US$6.5 Million In Venture Financing 20
Aduro BioTech Secures US$0.5 Million In Venture Financing 21
Aduro BioTech Secures US$19.25 Million In Series B Financing 22
Aduro BioTech Raises US$0.77 Million In Venture Financing 23
University of California, Berkeley Enters into Agreement with Aduro Biotech 24
Aduro Biotech Enters into Agreement with Novartis for Immuno-Oncology Products 25
Aduro BioTech Enters Into Co-Development Agreement With Protein Potential And Sanaria To Develop Malaria Vaccines 26
Aduro BioTech Amends Licensing Agreement with University of California, Berkeley 28
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 29
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech 31
Aduro BioTech Enters into Licensing Agreement with University of California, Berkeley 32
Aduro BioTech Enters into Exclusive Licensing Agreement with Janssen Biotech 34
Aduro BioTech Enters into Licensing Agreement with Janssen Biotech for GVAX technology 35
Aduro BioTech Enters into Licensing Agreement with Karagen Pharma 37
Aduro BioTech Enters into Licensing Agreement with UCB 38
BioSante Pharma Enters Into Licensing Agreement With Aduro BioTech 40
Aduro BioTech Enters into Licensing Agreement with Johns Hopkins University 41
Aduro BioTech Raises USD25 Million in Private Placement Shares 43
Aduro BioTech Raises USD136.8 Million in IPO 45
Aduro Biotech to Acquire BioNovion 47
Consegna Group Completes Acquisition Of Aspen Medisys 48
Aduro BioTech, Inc., Key Competitors 50
Aduro BioTech, Inc., Key Employees 51
Aduro BioTech, Inc., Subsidiaries 52
List of Figures
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Aduro BioTech, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
